# Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

> **NCT00571649** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 8101 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Enoxaparin
- **DRUG:** Rivaroxaban placebo
- **DRUG:** Enoxaparin placebo

## Key facts

- **NCT ID:** NCT00571649
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-08
- **Final completion:** 2010-11
- **Target enrollment:** 8101 (ACTUAL)
- **Last updated:** 2016-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00571649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00571649, "Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00571649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*